Edelweiss MSCI India Domestic & World Healthcare 45 Index Fund
The scheme seeks to invest in stocks comprising of the MSCI India Domestic & World Healthcare 45 Index with the objective to provide investment returns that, before expenses, closely corresponds to the returns equivalent to the index, subject to tracking errors.
Growthvine rating: 4/5 — ranked #25 of 245 in category.
Fund basics
| Category | Equity: Index |
|---|
| NAV | ₹25.28 (as of 2026-11-13) |
|---|
| AUM | ₹192 Cr |
|---|
| Expense ratio | 0.90% |
|---|
| Riskometer | Very High |
|---|
| Fund manager | Bhavesh Jain |
|---|
| Exit load | 0 |
|---|
Performance & risk
| 5-year annualised return | 14.19% |
|---|
| Sharpe ratio | 1.23 |
|---|
| Standard deviation | 12.08% |
|---|
| Max drawdown | −16.69% |
|---|
| Alpha | 3.93 |
|---|
| Beta | 0.65 |
|---|
Market cap allocation
| Large cap | 45.2% |
|---|
| Mid cap | 50.5% |
|---|
| Small cap | 4.3% |
|---|
Concentration
| Top 5 holdings | 34.3% |
|---|
| Top 10 holdings | 54.6% |
|---|
| Total holdings | 45 |
|---|
Top holdings
- Sun Pharmaceutical Industries Ltd. — 9.7%
- Eli Lilly & Co — 7.3%
- Divis Laboratories Ltd. — 7.1%
- Apollo Hospitals Enterprises Ltd. — 5.2%
- Laurus Labs Limited — 5.1%
- JOHNSON & JOHNSON — 4.3%
- Cipla Ltd. — 4.2%
- Dr. Reddys Laboratories Ltd. — 4.1%
- Torrent Pharmaceuticals Ltd. — 4.0%
- Max Healthcare Institute Limited — 3.7%
Top sectors
- Pharma & Biotech — 53.0%
- Global Equity — 32.1%
- Healthcare — 13.5%
Calendar-year track record
| Year | Return | Quartile | Category rank |
|---|
| 2026 (partial) | 21.5% | — | — |
| 2025 | 4.9% | — | — |
| 2024 | 28.9% | — | — |
| 2023 | 24.4% | — | — |
| 2022 | −5.3% | — | — |